Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients

NCT02529462 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

521

Enrollment

INDUSTRY

Sponsor class

Conditions

Depressive Disorder, Major

Interventions

GENETIC: NEUROPHARMAGEN-Guided Treatment
DRUG: Treatment As Usual

Sponsor

AB Biotics, SA